0000000000878609

AUTHOR

Anna Ferrari

showing 2 related works from this author

Early menopause is associated with lack of response to antiviral therapy in women with chronic hepatitis C.

2011

Background & Aims Chronic hepatitis C (CHC) and liver fibrosis progress more rapidly in men and menopausal women than in women of reproductive age. We investigated the associations among menopause, sustained virologic response (SVR), and liver damage in patients with CHC. Methods We performed a prospective study of 1000 consecutive, treatment-naive patients 18 years of age and older with compensated liver disease from CHC. Liver biopsy samples were analyzed (for fibrosis, inflammation, and steatosis) before patients received standard antiviral therapy. From women (n = 442), we collected data on the presence, type, and timing of menopause; associated hormone and metabolic features; serum lev…

Liver CirrhosisMaleTime Factorsmedicine.medical_treatmentBiopsyMenopause PrematuremenopauseHepacivirusmedicine.disease_causeGastroenterologySeverity of Illness IndexRisk FactorsOdds RatioProspective StudiesTreatment FailureProspective cohort studymedicine.diagnostic_testGastroenterologyAge FactorsHormone replacement therapy (menopause)Hepatitis CMiddle AgedViral LoadImmunohistochemistryMenopauseItalyLiver biopsyRNA ViralFemaleInflammation Mediatorshcv svr menopauseViral loadAdultmedicine.medical_specialtyantiviral therapy; menopause; prognostic factors; hcv therapyGenotypeHepatitis C virusAntiviral AgentsRisk AssessmentSex FactorsInternal medicinehcvmedicineHumanshcv; ifn; menopauseHepatologybusiness.industryInterleukin-6Tumor Necrosis Factor-alphaOdds ratioHepatitis C Chronicmedicine.diseaseifnEndocrinologyLogistic ModelsbusinessBiomarkersGastroenterology
researchProduct

Enoxaparin Prevents Portal Vein Thrombosis and Liver Decompensation in Patients With Advanced Cirrhosis

2012

BACKGROUND & AIMS: We performed a randomized controlled trial to evaluate the safety and efficacy of enoxaparin, a low-molecular-weight heparin, in preventing portal vein thrombosis (PVT) in patients with advanced cirrhosis. METHODS: In a nonblinded, single-center study, 70 outpatients with cirrhosis (Child-Pugh classes B7-C10) with demonstrated patent portal veins and without hepatocellular carcinoma were assigned randomly to groups that were given enoxaparin (4000 IU/day, subcutaneously for 48 weeks; n = 34) or no treatment (controls, n = 36). Ultrasonography (every 3 months) and computed tomography (every 6 months) were performed to check the portal vein axis. The primary outcome was pre…

medicine.medical_specialtyCirrhosisIntention-to-treat analysisHepatologybusiness.industrycirrhosisGastroenterologyPortal vein trombosis; Enoxaparin; cirrhosisenoxaparin cirrhosis portal thrombosismedicine.diseasePortal vein trombosisSurgeryPortal vein thrombosislaw.inventionSpontaneous bacterial peritonitisModel for End-Stage Liver DiseaseRandomized controlled triallawHepatocellular carcinomaMedicinePortal hypertensionEnoxaparinbusinessGastroenterology
researchProduct